z-logo
Premium
Factor VIII inhibitor bypassing activity (FEIBA) – addressing safety issues
Author(s) -
ALEDORT L. M.
Publication year - 2008
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2007.01594.x
Subject(s) - medicine , tolerability , haemophilia , anamnesis , intensive care medicine , clinical trial , adverse effect , surgery
Summary.  Bypassing therapy is usually necessary to control or prevent bleeding episodes in patients with haemophilia A or B and high‐titre inhibitors. Factor VIII inhibitor bypassing activity (FEIBA) has a long history of successful use in the acute, surgical and prophylactic treatment settings, but safety concerns have made some reluctant to administer this bypassing agent. A review of the literature and clinical trial data show that FEIBA has a low prevalence of thrombosis, a low prevalence of anamnesis that does not impact haemostatic efficacy and an excellent record of pathogen safety and clinical tolerability.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here